How big is the Radiopharmaceutical Theranostics Market?

The Radiopharmaceutical Theranostics Market size is expected to reach USD 2.11 billion in 2024 and grow at a CAGR of 11.07% to reach USD 3.56 billion by 2029. Read More

What is the current Radiopharmaceutical Theranostics Market size?

In 2024, the Radiopharmaceutical Theranostics Market size is expected to reach USD 2.11 billion. Read More

Who are the key players in Radiopharmaceutical Theranostics Market?

Bayer AG, Cardinal Health, GE HealthCare, Novartis AG and Jubilant Pharmova Limited (Jubilant Radiopharma) are the major companies operating in the Radiopharmaceutical Theranostics Market. Read More

Which is the fastest growing region in Radiopharmaceutical Theranostics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Radiopharmaceutical Theranostics Market?

In 2024, the North America accounts for the largest market share in Radiopharmaceutical Theranostics Market. Read More

What years does this Radiopharmaceutical Theranostics Market cover, and what was the market size in 2023?

In 2023, the Radiopharmaceutical Theranostics Market size was estimated at USD 1.88 billion. The report covers the Radiopharmaceutical Theranostics Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Radiopharmaceutical Theranostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Radiopharmaceutical Theranostics Market Share

Statistics for the 2023 & 2024 Radiopharmaceutical Theranostics market share, created by Mordor Intelligence™ Industry Reports. Radiopharmaceutical Theranostics share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Radiopharmaceutical Theranostics Industry

The radiopharmaceutical theranostics market is consolidated due to the presence of four to five major companies dominating it. Ongoing advancement efforts by major players such as Bayer AG, Cardinal Health, GE HealthCare, Jubilant Radiopharma, and Novartis AG for development, including the discovery of new tracers, ligands, and targeting agents, contribute to the market’s consolidation. These companies continually explore novel approaches, resulting in a diverse array of radiopharmaceutical products.